Entering of Phase II Study for Enterovirus Vaccine

Medigen Vaccinology Corp., a subsidiary of Medigen Biotech Corp. has entered phase II study for Enterovirus EV-71 vaccine clinical trials on November 19, 2014. This trial was implemented by NTU Medical Hospital’s National Center of Excellence for Clinical of Excellence for Clinical Trial & Research and led by Dr. Li-Min Huang. This clinical trial expects to recruit 365 subjects in four different age groups for vaccination. Every subject will be tested and tracked for the immune response after vaccination.